Predicting response to PD-1 immunotherapy in advanced lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify biomarkers that can predict the response and toxicity of PD-1 immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). By analyzing tumor microenvironments using advanced imaging techniques, the study seeks to uncover immunophenotypic signatures associated with treatment outcomes. Patients who received pembrolizumab as a first-line treatment between January 2017 and December 2019 will be evaluated based on their response and adverse effects. The findings could lead to improved patient selection and treatment strategies in immuno-oncology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients
* Advanced NSCLC with PD-L1 TPS of 50% or greater
* Administration of first line pembrolizumab between January 2017 \& December 2019

Exclusion Criteria:

* Auto-immune disease
* Prior exposure to immunotherapy
* First dose pembrolizumab administered after December 2019

Where it's running

• CHRU de Brest
  Brest, France Recruiting

Study contacts

• Principal investigator: Margaux GEIER, MD — Chru Brest
• Study coordinator: Margaux GEIER, MD
• Email: margaux.geier@chu-brest.fr
• Phone: 02 30 33 80 30

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

  This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07668037

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

• Lorlatinib with local consolidation therapy for ALK-positive advanced non-small cell lung cancer

  This trial will test whether adding local consolidation treatments to lorlatinib helps people with ALK-positive advanced non-small cell lung cancer stay progression-free longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07415005

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.